[1] |
Boers E, Barrett M, Su JG, et al. Global burden of chronic obstructive pulmonary disease through 2050[J]. JAMA Netw Open, 2023, 6(12):e2346598.
|
[2] |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the global burden of disease study 2017[J]. Lancet, 2019, 394(10204):1145-1158.
doi: S0140-6736(19)30427-1
pmid: 31248666
|
[3] |
GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Respir Med, 2020, 8(6):585-596.
doi: 10.1016/S2213-2600(20)30105-3
pmid: 32526187
|
[4] |
Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis[J]. Lancet Respir Med, 2022, 10(5):447-458.
doi: 10.1016/S2213-2600(21)00511-7
pmid: 35279265
|
[5] |
Chen S, Kuhn M, Prettner K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: A health-augmented macroeconomic modelling study[J]. Lancet Glob Health, 2023, 11(8):e1183-e1193.
|
[6] |
Tsay JJ, Segal LN. Could the sputum microbiota be a biomarker that predicts mortality after acute exacerbations of chronic obstructive pulmonary disease?[J]. Am J Respir Crit Care Med, 2019, 199(10):1175-1176.
|
[7] |
Russo C, Colaianni V, Ielo G, et al. Impact of lung microbiota on COPD[J]. Biomedicines, 2022, 10(6):1337.
|
[8] |
Martin R, Nora M, Anna L, et al. Altered hypoxia-induced cellular responses and inflammatory profile in lung fibroblasts from COPD patients compared to control subjects[J]. Respir Res, 2024, 25(1):282.
|
[9] |
郑成玲, 蒋慧生, 王金鹏. 老年COPD合并肺部感染患者血清免疫状态变化吸预后价值[J]. 疑难病杂志, 2023, 22(12):1268-1272+1284.
|
[10] |
van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping[J]. Scientometrics, 2010, 84(2):523-538.
pmid: 20585380
|
[11] |
Arruda H, Silva ER, Lessa M, et al. VOSviewer and bibliometrix[J]. J Med Libr Assoc, 2022, 110(3):392-395.
doi: 10.5195/jmla.2022.1434
pmid: 36589296
|
[12] |
Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: Visualization and knowledge discovery in bibliographic databases[J]. AMIA Annu Symp Proc, 2005, 2005:724-728.
|
[13] |
Chen C, Dubin R, Kim MC. Emerging trends and new developments in regenerative medicine: Ascientometric update (2000-2014)[J]. Expert Opin Biol Ther, 2014, 14(9):1295-1317.
|
[14] |
Chen C. Searching for intellectual turning points: Progressive knowledge domain visualization[J]. Proc Natl Acad Sci U S A, 2004, 101 Suppl 1(Suppl 1):5303-5310.
|
[15] |
Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China[J]. Allergy, 2020, 75(7):1730-1741.
|
[16] |
Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence[J]. Nature, 2014, 505(7483):412-416.
|
[17] |
Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases[J]. Lancet, 2014, 384(9944):691-702.
doi: 10.1016/S0140-6736(14)61136-3
pmid: 25152271
|
[18] |
Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease[J]. N Engl J Med, 2008, 359(22):2355-2365.
|
[19] |
Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease[J]. N Engl J Med, 2002, 347(7):465-471.
|
[20] |
Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD[J]. PLoS One, 2011, 6(2):e16384.
|
[21] |
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2013, 187(4):347-365.
|